Cocrystal Pharma, Inc. (NASDAQ:COCP)
Industry: Healthcare

Cocrystal Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of various antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza. It is also involved in identifying and developing various non-nucleoside polymerase inhibitors for norovirus gastroenteritis. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck & Co., Inc. to discover and develop proprietary influenza A/B antiviral agents; and a collaboration agreement National Institute of Health. The company was founded in 2007 and is headquartered in Tucker, Georgia.

Current Quote*
Last: $1.375
Change: 0.075
Book: $0.655
Volume: 740

As Of: 10/18 13:01 ET
*Quotes delayed by 20min.

Graphs for COCP


3 Month Graph


6 Month Graph


1 Year Graph